Bausch + Lomb (BLCO) Proxy Filing summary

Executive summary

• Achieved 16% reported and 17% constant currency revenue growth in 2024, driven by new product launches and leadership in key categories such as dry eye.

• Enhanced R&D capabilities and pipeline, positioning for near- and long-term success.

• Focused on operational excellence, supply chain optimization, and innovation as core strategies.

• 2024 financials: $4.79B GAAP revenue, ($317M) net loss, $878M adjusted EBITDA, $232M cash from operations.

• Above-target performance led to 107% bonus funding under the annual incentive program.

Voting matters and shareholder proposals

• Shareholders to vote on: election of ten directors, advisory approval of executive compensation, appointment of PwC as auditor, and receipt of 2024 audited financials.

• Board recommends voting FOR all proposals.

• Annual meeting to be held virtually on May 21, 2025.

Board of directors and corporate governance

• Ten director nominees, nine of whom are independent; diverse backgrounds in finance, healthcare, operations, and governance.

• Board committees: Audit and Risk, Talent and Compensation, Nominating and Corporate Governance, Science and Technology.

• Lead Independent Director role ensures independent oversight; annual board and committee self-assessments conducted.

• Director share ownership guidelines require holding equity valued at five times the annual cash retainer within five years.

• Board regularly reviews succession planning and director education.